Introduction
The Pdcd4 gene (also known as MA-3, TIS, H731 and DUG) has originally been identified as a gene whose expression is strongly induced during apoptosis in various murine cells (Shibahara et al., 1995;  for recent reviews, see Lankat-Buttgereit and Go¨ke, 2003; Young et al., 2003) . Independently of this it was shown that Pdcd4 is a direct target gene of the hematopoietic transcription factor c-Myb and its oncogenic homolog v-Myb (Schlichter et al., 2001a, b; Appl and Klempnauer, 2002) . Finally, and most interestingly, Pdcd4 has been identified as a transformation suppressor gene in a mouse keratinocyte model of tumor promotion (Cmarik et al., 1999) . Pdcd4 expression was found to be high in a keratinocyte cell line that was resistant to transformation by the tumor promoter TPA, whereas a related cell line that was efficiently transformed by the tumor promoter expressed Pdcd4 at a low level. Upregulation of Pdcd4 rendered these cells resistant to transformation by the tumor promoter, while antisense-mediated downregulation of Pdcd4 resulted in higher transformation rates. Furthermore, it was shown that Pdcd4 expression inhibits transactivation and transformation mediated by the transcription factor AP-1, a known target of TPAinduced signaling pathways (Yang et al., 2001 (Yang et al., , 2003b . These findings suggested that the Pdcd4 protein might inhibit neoplastic transformation by disrupting signal transduction pathways that activate AP-1. Recently, Pdcd4 has also been implicated as a potential tumor suppressor gene in the development of human lung cancer (Chen et al., 2003) .
The molecular function of Pdcd4 is presently not fully understood. Several lines of evidence have suggested that Pdcd4 plays a role in RNA metabolism and/or protein translation. The protein encoded by Pdcd4 (referred to as Pdcd4) shares homology with eucaryotic translation initiation factors and has been shown to interact with eIF4A and eIF4G (Go¨ke et al., 2002; Kang et al., 2002; Yang et al., 2003a) . It was demonstrated that Pdcd4 inhibits the helicase activity of translation initiation factor eIF4A and suppresses cap-dependent translation initiation of model RNA substrates (Yang et al., 2003a) . These observations support the view that the Pdcd4 protein plays a role in protein translation, however, so far translational targets of Pdcd4 have not been rigorously identified. In addition to its presumed role in protein translation, Pdcd4 also appears to act in the nucleus. We have recently shown that Pdcd4 is a nuclear/cytoplasmic shuttling protein whose subcellular distribution is affected by the growth conditions, such as serum content of the medium (Bo¨hm et al., 2003) . The nuclear export of the protein is Crm1-dependent and is mediated by two potent nuclear export signals. Furthermore, the Pdcd4 protein has intrinsic RNA-binding activity, suggesting that it might be involved in some aspect of RNA metabolism (Bo¨hm et al., 2003) . Whether Pdcd4 binds to specific RNA species is not known at present.
One of the most interesting properties of Pdcd4 is its ability to suppress TPA-induced transformation of mouse keratinocytes. Yang et al. (2001) have made the intriguing observation that Pdcd4 inhibits the activation of AP-1-dependent reporter genes by c-Jun, suggesting that the Pdcd4 protein might inhibit neoplastic transformation by blocking the function of c-Jun. Here, we have addressed the mechanism by which Pdcd4 affects cJun activity. Our data suggest that Pdcd4 interferes with the phosphorylation of c-Jun by Jun-N-terminal-kinase (JNK) and the recruitment of coactivator p300 by c-Jun.
Results

Pdcd4 inhibits transactivation mediated by a c-Jun-C/ EBPb fusion protein
Previous work has shown that Pdcd4 inhibits c-Jundependent transactivation of an AP-1 responsive reporter gene (Yang et al., 2001) . To determine whether the inhibitory effect of Pdcd4 is mediated by the DNA binding or transactivation domain of c-Jun, we made use of a mutant of c-Jun whose DNA-binding domain has been replaced by that of the transcription factor C/ EBPb. We cotransfected an expression vector for this hybrid transactivator together with a C/EBP-responsive reporter plasmid into a fibroblast line (QT6), which contains low levels of endogenous C/EBP factors. As shown in Figure 1 , the Jun-C/EBPb protein increased the activity of the promoter in the absence of Pdcd4, as expected. However, in the presence of Pdcd4, the activity of the promoter was significantly suppressed. When C/ EBPb was used instead of the Jun-C/EBPb hybrid protein to drive the reporter gene, Pdcd4 had no effect. We concluded from these results that the inhibition of Jun-dependent transactivation by Pdcd4 is mediated by the Jun transactivation domain.
Pdcd4 expression interferes with the phosphorylation of c-Jun
To further explore how Pdcd4 inhibits transactivation mediated by the Jun-C/EBPb protein, we first analysed extracts of the transfected cells by Western blotting to determine whether Pdcd4 has any effect on the hybrid protein. As illustrated in Figure 2 , this was indeed the case. Figure 2a shows that C/EBPb-specific antibodies detect two forms of the Jun-C/EBPb protein, which migrate differently in an SDS-polyacrylamide gel. Both forms appeared to be equally abundant in the absence of Pdcd4; however, in the presence of Pdcd4, the slowermigrating form of the protein was present in much smaller amounts. This effect of Pdcd4 was specific for Jun-C/EBPb; when Pdcd4 was coexpressed with C/ EBPb, no change in protein mobility was observed (Figure 2d ), suggesting that the Jun part of Jun-C/EBPb is responsible for the differences in electrophoretic mobility.
The transactivation domain of Jun is phosphorylated by the Jun-N-terminal-kinase (JNK) at serines 63 and 73 and threonines 91 and 93 and the integrity of these phosphorylation sites is essential for target gene activation by Jun , Hibi et al., 1993 Derijard et al., 1994; Papavassiliou et al., 1995) . We therefore considered the possibility that the slowermigrating species of Jun-C/EBPb is a phosphorylated form of the protein, and that Pdcd4 suppresses the phosphorylation by JNK, thereby inhibiting the activity of the protein. To address this possibility, we probed extracts of the transfected cells with an antiserum that is specific for c-Jun phosphorylated at serine 63. Figure 2b shows that the antiserum reacted preferentially with the slower-migrating form of the protein, suggesting that phosphorylated Jun-C/EBPb is enriched in this fraction. In addition, the phosphorylation-specific antiserum reacts with a diffuse smear of bands migrating even slower. We presume that these mobility shifts are due to phosphorylation of multiple residues in the c-Jun transactivation domain. In the presence of Pdcd4, the amount of the phosphorylated forms is reduced, consistent with the notion that Pdcd4 inhibits the phosphorylation of Jun-C/EBPb. To demonstrate that the inhibition of phosphorylation by Pdcd4 is not an artifact of the Jun-C/EBPb hybrid protein we cotransfected expression vectors for cJun and Pdcd4 followed by Western blot analysis using Jun-specific and phospho-Jun-specific antibodies ( Figure 3a) . As seen in the left panel of Figure 3a , the Jun-specific antibody detected a smear of slowermigrating bands in addition to the full-length Jun protein. In the presence of Pdcd4, this slower-migrating material was not visible. The phospho-Jun-specific antiserum reacted with the slower-migrating material much stronger and the amount of this material was again significantly reduced in the presence of Pdcd4. In addition to this reduction in the amount of phosphorylated forms of c-Jun, we noted that there is also some decrease in the total amount of c-Jun in the presence of Pdcd4.
To corroborate the idea that Pdcd4 interferes with the phosphorylation of Jun, we made use of a mutant in which all JNK phosphorylation sites of c-Jun have been mutated to alanines. This mutant as well as wild-type cJun was then coexpressed with Pdcd4, followed by Western blotting with Jun-specific antiserum (Figure 3b ). The amount of wild-type c-Jun was again decreased by Pdcd4 expression, whereas the mutant Jun was not affected. Western blotting using the phospho-Junspecific antiserum again showed a strong decrease of the phosphorylated forms of wild-type c-Jun (Figure 3c ), whereas the mutant Jun did not react with the antiserum, as expected (data not shown).
Phosphorylation of c-Jun by JNK requires the presence of the so-called d-domain of c-Jun, which serves as a docking site for JNK (Dai et al., 1995; Kallunki et al., 1996) . To gather further evidence that Pdcd4 interferes with JNK-dependent phosphorylation of c-Jun, we also assessed the effect of Pdcd4 on a deletion mutant of Jun lacking the d-domain. As shown in Figure 3b , Pdcd4 did not noticeably affect the deletion mutant, consistent with the notion that Pdcd4 counteracts JNK-dependent phoshorylation of Jun.
Conditional expression of Pdcd4 in a human cell line inhibits phosphorylation of c-Jun
The work described above suggested that Pdcd4 expression interferes with JNK-dependent phosphorylation of Since only a small fraction of the total cell population usually takes up the transfected DNA in these experiments, it is difficult to analyse the effect of Pdcd4 on individual endogenous proteins or on the behavior of the transfected cells. To circumvent these problems, we generated a stable subclone of the human 293 cell line that permits conditional expression of the Pdcd4 protein, using the tetracyclin-inducible T-Rex expression system. Stable transfectants of 293 cells were selected in the absence of Pdcd4 expression and were subsequently analysed for inducibility of Pdcd4 expression. Figure 4a shows a Western blot analysis of such a clone (referred to as ZB-2). The Pdcd4 protein is virtually undetectable if the cells are kept in the absence of doxycyclin (an analog of tetracyclin) but is strongly induced after addition of doxycyclin to the culture medium. Time course experiments showed that maximal induction is reached 1 day after addition of doxycyclin (data not shown). Analysis the subcellular distribution of Pdcd4 by immunofluorescence microscopy showed that the protein was predominantly located in the nuclei of ZB-2 cells (Figure 4d ), in agreement with earlier results (Bo¨hm et al., 2003) . (d) ZB-2 cells grown in the absence (upper panels) or in the presence (lower panels) of doxycyclin were analysed by immunofluorescence microscopy using an HA-specific monoclonal antibody (left panels) or by phase contrast microscopy (right panels). (e) Extracts from ZB-2 cells grown for 24 h with ( þ ) or without (À) doxycyclin were analysed by Western blotting using anti-JNK antibodies. (f) Extracts from ZB-2 cells grown in the presence or absence of doxycyclin were incubated with GST (lanes 1 and 3) or with a GST-Jun(1-135) fusion protein (lanes 2 and 4) immobilized on glutathione-sepharose. The sepharose beads were then subjected to an in vitro kinase assay and radiolabeled proteins were analysed by SDS-PAGE and autoradiography. (g) Extracts from ZB-2 cells grown in the presence or absence of doxycyclin were incubated with GST-Jun(1-135) immobilized on glutathione-sepharose. The beads were then subjected to an nonradioactive in vitro kinase assay and the phosphorylation of GST-Jun(1-135) was monitored by Western blotting with phospho-Jun-specific antibodies. Lane 3 shows a control containing the same amount of GST-Jun(1-135) not incubated with cell extract
Since Pdcd4 expression has been linked to apoptosis in earlier work (Shibahara et al., 1995) , we investigated whether Pdcd4 has any effect on the growth rate of the cells expressing it. To this end we followed the increase in cell number of clone ZB-2 in the presence or absence of doxycyclin over a period of several days. As seen in Figure 4c , the cells grew with identical doubling times of approximately 24 h irrespectively of whether doxycyclin was present or not. Thus, Pdcd4 overexpression has no effect on the growth of 293 cells. There was also no obvious accumulation of apoptotic cells under these conditions, indicating that Pdcd4 expression by itself does not induce apoptosis, at least not in 293 cells. We also compared the response of ZB-2 cells grown in the absence or presence of doxycyclin to an apoptotic stimulus such as UV-irradiation, but failed to see any effect of Pdcd4 on apoptotic cell death (data not shown). Thus, Pdcd4 expression in this system seems neither to advance nor to delay or prevent apoptosis.
To determine whether Pdcd4 affects the phosphorylation of endogenous c-Jun, we analysed extracts of clone ZB-2 grown in the presence or absence of doxycyclin by Western blotting using the phospho-Jun-specific antiserum. Figure 4b shows that the amount of phosphorylated Jun was decreased in the presence of doxycyclin, thus confirming that Pdcd4 interferes with the phosphorylation of c-Jun at JNK phosphorylation sites.
Pdcd4 interacts with c-Jun and JNK-1 in vitro
We considered several possible mechanisms to account for the inhibitory effect of Pdcd4 on the phosphorylation of Jun. First, we asked whether Pdcd4 downregulates the expression of JNK. Figure 4e shows a Western blot of extracts of ZB-2 cells grown in the absence or presence of doxycyclin and stained with an antiserum that recognizes JNK-1 and JNK-2. As seen in this figure, there was no significant change in the amount of both kinases following doxycyclin treatment. We then considered the alternative possibility that Pdcd4 affects JNK activity by disrupting signaling pathways upstream of JNK. To measure JNK kinase activity in ZB-2 cells, we immobilized a GST-Jun(1-135) fusion protein on glutathione-sepharose beads, followed by incubation of the beads with extract of clone ZB-2 cells grown in the absence or presence of doxycyclin. Subsequently, the beads were washed and incubated with g 32 P-ATP and the kinase activity was quantified by running the GST-Jun(1-135) protein on an SDSpolyacrylamide gel and analysing the incorporated radioactivity. As illustrated in Figure 4f , the JNK activity of ZB-2 cells grown in the presence or absence of doxycyclin was indistinguishable. To corroborate this result, we also performed a nonradioactive in vitro kinase assay of extracts of ZB-2 cells grown in the presence or absence of doxycyclin. In this assay, the phosphorylation of c-Jun was specifically monitored by an antiserum that is specific for c-Jun phosphorylated at serine 63. Again, there was no significant difference of JNK activity in ZB-2 cells grown in the presence or absence of doxycyclin. Thus, Pdcd4 seems not to interfere with c-Jun phosphorylation by simply downregulating JNK expression or by disrupting signaling pathways upstream of JNK.
To further explore the mechanism by which Pdcd4 inhibits the phosphorylation of Jun, we considered the possibility that Pdcd4 interacts with Jun and thereby inhibits its phosphorylation. To address this possibility, we performed in vitro protein interaction assays. Extracts of cells transfected with expression vectors for HA-tagged versions of wild-type c-Jun, the Jun-Ala mutant and the deletion mutant c-Jun D31-57 were incubated with a GST-Pdcd4 fusion protein immobilized on glutathione-sepharose beads. The bound proteins were then analysed by Western blotting using HAspecific antiserum. Figure 5a shows that c-Jun was indeed able to bind to GST-Pdcd4, whereas control incubations using sepharose beads loaded with an equivalent amount of GST failed to show binding. For comparison, we performed a similar binding experiment with extracts of cells transfected with an expression vector for the eucaryotic translation initiation factor eIF4A, whose interaction with Pdcd4 has previously been reported (Go¨ke et al., 2002; Yang et al., 2003a) . As shown in Figure 5b , we confirmed the interaction of Pdcd4 with eIF4A, moreover, this experiment shows that c-Jun and eIF4A interact with roughly similar efficiency with Pdcd4. We also assessed the ability of JNK-1 to interacxt with Pdcd4 (Figure 4c ). It is evident that GST-Pdcd4 also binds to JNK-1, although the binding seems to be somewhat weaker.
The GST-pulldown experiments illustrated in Figure 4 suggested that Pdcd4 might inhibit JNK-dependent phosphorylation of c-Jun by interacting with c-Jun as well as with JNK-1. To further explore this possibility, we investigated whether Pdcd4 is able to inhibit the phosphorylation of Jun by JNK in an in vitro kinase reaction. In this experiment, we used GST-Jun(1-135) as a substrate for JNK-1 which was immunoprecipitated by Flag-antibodies from extracts of Flag-JNK-1-transfected cells. As shown in Figure 6 , c-Jun was phosphorylated by the kinase, as expected. The phosphorylation was specific as a control reaction using a Flag-immunoprecipitate from untransfected cells did not phosphorylate c-Jun. When stoichiometric amounts of bacterially expressed, full-length Pdcd4 were added to the reaction, the phosphorylation of c-Jun was significantly decreased, demonstrating that Pdcd4 inhibits JNK-1-dependent phosphorylation of c-Jun not only in vivo but also in an in vitro kinase reaction.
Pdcd4 interferes with the interaction of c-Jun and p300
Phosphorylation of c-Jun by JNK results in an increase of the transactivation potential of the protein which is mediated, at least in part, by the recruitment of coactivators such as p300 or CBP (Bannister et al., 1995; Lee et al., 1996) . It has been recently suggested that phosphorylation of Jun stimulates the binding of these coactivators by an indirect mechanism involving the dissociation of an as yet unknown inhibitory factor (Weiss et al., 2003) . Since our data suggest that Pdcd4
Transformation suppressor Pdcd4 N Bitomsky et al interacts with c-Jun and inhibits its phosphorylation by JNK, we were interested to know whether Pdcd4 has any effect on the recruitment of p300 by c-Jun. We have recently shown that recruitment of p300 by c-Jun and several other transcription factors triggers the phosphorylation of the carboxyterminal region of p300 (Schwartz et al., 2003) . This phosphorylation can be easily monitored by analysing the electrophoretic mobility of the carboxyterminal domain of p300 in an SDS-polyacrylamide gel. To investigate whether Pdcd4 affects the Jun-induced phosphorylation of p300, we cotransfected expression vectors for c-Jun, the carboxyterminal domain of p300 and increasing amounts of Pdcd4 into a fibroblast cell line followed by SDS-PAGE and Western blotting to determine the mobility of p300. As expected from our previous work (Schwartz et al., 2003) , in the presence of c-Jun, multiple slowermigrating forms of the p300 carboxyterminal domain accumulated, giving rise to a rather broad smear of bands ( Figure 7a ). Adding increasing amounts of Pdcd4 resulted in a partial suppression of the appearance of these slower-migrating forms of p300, suggesting that Pdcd4 interferes with the interaction of p300 and c-Jun or with the subsequent phosphorylation of p300. To discern these possibilities, we performed a mammalian two-hybrid experiment (Figure 7b ), using Gal4/c-Jun and p300/VP16 fusion constructs. The p300/VP16 fusion protein contains the E1A-binding region of p300, which has been shown to interact with c-Jun (Lee et al., 1996) . Figure 7b shows that p300/VP16 increases the activity of the Gal4/c-Jun protein, as expected, if both proteins interact. Expression of increasing amounts of Pdcd4 gradually diminished the ability of p300/VP16 to stimulate the activity of the Gal4/c-Jun protein, consistent with the notion that Pdcd4 blocks the interaction of c-Jun and p300. We also performed a similar experiment using an expression vector for full-length p300 instead of the p300/VP16 construct. p300 stimulated the activity of Gal4/c-Jun, as expected. As seen in the previous experiment, the stimulation by p300 was severely compromised by increasing amounts of Pdcd4 (Figure 7c ). Taken as a whole, the experiments shown in Figure 7 provide strong evidence that Pdcd4 disrupts the cooperation of c-Jun and p300.
Discussion
The Pdcd4 gene has attracted substantial attention because of its ability to suppress the transformation of the mouse keratinocyte line JB6, a well-studied model of tumor promotion (Cmarik et al., 1999) . Recent work has implicated the Pdcd4 gene as a potential tumor suppressor gene in the development of lung cancer (Chen et al., 2003) . Analyses of the molecular function of Pdcd4 suggest that the protein may play multiple roles. Pdcd4 interacts with eucaryotic translation initiation factors eIF4A and eIF4G and has been shown to interfere with cap-dependent translation of model substrate RNAs, suggesting that it performs a regulatory role during protein translation (Go¨ke et al., 2002; Yang et al., 2003a Yang et al., , 2004 . Consistent with this notion, the Pdcd4 protein was found to occupy a perinuclear location (Yang et al., 2003a) . However, conclusive evidence supporting a regulatory role of Pdcd4 in protein translation is still missing as no translational target of Pdcd4 has been rigorously identified. LankatButtgereit et al. (2004) have recently reported that the levels of carbonic anhydrase type II decrease in response to Pdcd4 overexpression; however, since the carbonic anhydrase type II gene is an AP-1 target (David et al., 2001) , it is not clear whether this effect of Pdcd4 is exerted on the transcriptional or translational level. We and others Bo¨hm et al., 2003) have reported that the Pdcd4 protein is located in the cell nucleus, at least under certain conditions, suggesting that Pdcd4 might also have nuclear functions. A possible explanation for the discrepancies in the different Transformation suppressor Pdcd4 N Bitomsky et al subcellular localizations reported for the protein is provided by our observation that the Pdcd4 protein contains two nuclear export signals and is exported from the nucleus by an leptomycin-B-dependent mechanism under certain conditions, such as serum starvation (Bo¨hm et al., 2003) . This suggests that the protein can be predominantly nuclear or cytoplasmic, depending on the state of the cell. Thus, these observations suggest that in addition to its role in cytoplasmic protein translation, Pdcd4 may also perform functions in the nucleus.
Initial evidence for a nuclear function of Pdcd4 was provided by Yang et al. (2001) who have observed that Pdcd4 interferes with the activity of the transcription factor c-Jun. Our data suggest a mechanistic explanation for the inhibition of c-Jun by Pdcd4. In transiently transfected cells as well as in a conditional Pdcd4 expression system, we observed that Pdcd4 suppresses the phosphorylation of c-Jun at amino-acid residues, which are known to be phosphorylated by the JNK kinase pathway. Phosphorylation of c-Jun by JNK is crucial for the transactivation of downstream target genes and the oncogenic potential of c-Jun Smeal et al., 1991; Hibi et al., 1993; Derijard et al., 1994) , hence the ability to inhibit JNK signaling provides a straightforward explanation for the inhibitory effect of Pdcd4 on c-Jun activity.
In transient transfection experiments, we have also observed a decrease of the amount of c-Jun following Pdcd4 expression. Presumably, this is an indirect consequence of inhibiting the phosphorylation of cJun. The half-life of c-Jun is known to be increased following phosphorylation by JNK kinase (Fuchs et al., 1996 (Fuchs et al., , 1997 . Inhibition of phosphorylation will therefore destabilize the protein. Our observation that the amounts of c-Jun mutants, which cannot be phosphorylated by JNK, do not decrease in the presence of Pdcd4, is in accordance with this notion.
The in vitro binding experiments reported here raise the possibility that Pdcd4 perturbs the interplay between c-Jun and JNK by interacting with c-Jun as well as with JNK-1. Consistent with this idea, Pdcd4 inhibits JNK-1-dependent phosphorylation of c-Jun in an in vitro kinase reaction, an observation which excludes many alternative explanations, such as disruption of JNK-signaling upstream of JNK or effects on the expression level of JNK. In vivo experiments so far have failed to show coprecipitation of Pdcd4 with c-Jun or JNK-1, suggesting that these interactions might be relatively weak or transient. Nevertheless, weak interactions involving both c-Jun as well as JNK kinase might be sufficient to significantly decrease the phosphorylation of this substrate. How these interactions inhibit the phosphorylation of c-Jun is presently a matter of speculation. Obvious possibilities are that Pdcd4 inhibits the binding of JNK to c-Jun or simply blocks the phosphorylation sites in c-Jun. We have found that the c-Jun(D31-57) mutant still binds to Pdcd4. This mutant lacks the dregion of c-Jun, which has been implicated in the binding of JNK to c-Jun (Dai et al., 1995; Kallunki et al., 1996) . This suggests that JNK and Pdcd4 bind to different sequences within c-Jun. It is therefore conceivable that Pdcd4 binds to c-Jun and JNK-1 simultaneously, thereby disturbing their proper interaction. We have not observed that Pdcd4 itself is phosphorylated by JNK; Pdcd4 therefore is not simply an alternative substrate for JNK titrating out its activity.
Our work also provides the first evidence for a functional link between Pdcd4 and the coactivator p300 which binds to c-Jun and stimulates its transactivation potential (Bannister et al., 1995; Lee et al., 1996) . Our data suggest that Pdcd4 interferes with the recruitment of p300 by c-Jun, thereby providing an explanation for the inhibition of the transactivation potential of c-Jun by Pdcd4.
In summary, our work provides strong evidence for a direct involvement of Pdcd4 in the regulation of c-Jun activity. This function, which is presumably carried out in the nucleus, does not preclude additional roles of Pdcd4 in RNA metabolism or protein translation. It will be interesting to define these additional roles of Pdcd4 and to see if they are functionally linked. It is presently not known how suppression of Jun phosphorylation, which is seen at high Pdcd4 expression levels, relates to the normal function(s) of Pdcd4. In this respect, it would be very interesting to study the effect of a Pdcd4 'knockout' or 'knockdown' on the phosphorylation and activity of c-Jun. Preliminary evidence shows that Pdcd4 also inhibits JNK-dependent in vitro phosphorylation of a GST-Elk protein (data not shown); it will therefore also be very interesting to see if Pdcd4 regulates the activities of other transcription factors (such as Elk) by similar mechanisms as described here for c-Jun.
Materials and methods
Cell lines
QT6 quail fibroblasts (Moscovici et al., 1977) were grown in Iscove's modified DMEM supplemented with 8% fetal calf serum and 2% chicken serum. HEK-293 cells were grown in DMEM supplemented with 10% fetal calf serum.
Expression vectors
Expression vectors for C/EBPb, a Jun-C/EBPb hybrid protein and HA-tagged Pdcd4 have been described (Mink et al., 1996; Schlichter et al., 2001a) . Expression vectors for human c-Jun and Jun mutants c-Jun/Ala (ser63, ser73, thr91 and thr93 are replaced by alanine) and c-Jun/D31-57 (lacking amino acids 31-57) were obtained from D Bohmann and C Weiss and have been described (Treier et al., 1994 ). An expression vector for a Gal4/c-Jun(1-166) fusion protein was obtained from P Angel. The expression vectors for the C-terminal domain of p300 (pCDNA3-p300/1751-2370) and the p300/VP16 protein (containing amino acids 1752-1998 of human p300 fused to the VP16 transactivation domain) have been described (Mink et al., 1997; Schwartz et al., 2003) . The expression vector for full-length p300 (pCMV-p300CHA) was obtained from R Eckner (Eckner et al., 1994) . The expression vector for Flagtagged JNK-1 (pCDNA3-Flag-JNK-1) was obtained from R Davis. A bacterial expression vector for full-length mouse Pdcd4 fused to glutathione-S-transferase has been described Transformation suppressor Pdcd4 N Bitomsky et al (Bo¨hm et al., 2003) . The expression vector for GST-Jun(1-135) was obtained from E. Kerkhoff.
Reporter experiments and transfections
The luciferase reporter gene p-240Luc containing chicken mim-1 promoter sequences from 240 to þ 150 bp has been described (Ness et al., 1989) . The b-galactosidase reporter gene pCMVb was obtained from Clontech. DNA transfection was performed by calcium-phosphate co-precipitation, as described previously (Mink et al., 1996) . Cells were harvested 24 h after transfection and analysed for luciferase and b-galactosidase activity as previously described (Mink et al., 1996) .
Generation of stable transfectants
A tetracycline-inducible expression vector for HA-tagged Pdcd4 was generated by cloning the coding region for HAtagged chicken Pdcd4 protein (Schlichter et al., 2001a) into pCDNA4/TO/myc-His-A (Invitrogen). The resulting plasmid was then transfected simultaneously with pCDNA6-TR (encoding the tet-repressor) into 293 cells, followed by selection of stable transfectants in the presence of 750 mg/ml zeocin and 750 mg/ml blasticidin. Doxycyclin was omitted during the selection procedure to prevent Pdcd4 expression. Doubly resistant stable cell clones were then analysed by Western blotting for doxycyclin-inducible expression of HAtagged Pdcd4 protein. Clone ZB-2 was selected for further analysis.
Western blotting and immunofluorescence analysis
HA-tagged Pdcd4 protein was visualized on Western blots by the monoclonal HA-specific antibody HA.11. (BabCO). Jun-C/EBPb and C/EBPb were detected by an antiserum raised against chicken C/EBPb (Mink et al., 1996) . c-Jun was detected by using c-Jun-specific rabbit antiserum (sc-44, St. Cruz). Alternatively, a monoclonal antibody specific for c-Jun phosphorylated at serine 63 (sc-822, St. Cruz) was used. To detect JNK isoforms, JNK-1 antiserum (sc-571, St Cruz) was used. Flag-tagged JNK-1 was detected by anti-Flag antibody (Sigma). p300-specific antibodies (anti-p300, #05-267) were obtained from Upstate Biotechnology, Inc. Immunofluorescence analysis was performed with HA-specific antibodies as described (Schlichter et al., 2001a) .
Protein kinase assays
Flag-tagged JNK-1 was isolated by immunoprecipitation from QT6 cells transfected with expression vector pCDNA3-Flag-JNK-1 using anti Flag antibodies. To assay JNK-1 activity, glutathione-sepharose beads loaded with GST-Jun(1-135) were mixed with protein G sepharose beads carrying the immunoprecipitated Flag-JNK-1 and were incubated for 30 min at 371C in kinase buffer (25 mM Tris-HCl, pH 7.5; 5 mM b-glycerolphosphate; 2 mM DTT; 0.1 mM Na 3 VO 4 ; 10 mM MgCL 2 ; 20 mM ATP) containing 4 mCi of [g-32 P]ATP (Amersham, specific activity 3000 Ci/mmol). The reaction mixture was then subjected to electrophoresis in a 10% SDS-polyacrylamide gel and analysed with a phosphor-image analyser. In some experiments, bacterially expressed, fulllength Pdcd4 was added to the kinase reaction. To obtain this protein, GST-Pdcd4 was purified by binding to glutathionesepharose. Full-length Pdcd4 was then cleaved off the beads by incubation with prescission protease (Amersham).
JNK activity in ZB-2 cell extracts was analysed as follows. Cell extracts were prepared by lysing in buffer containing 50 mM Tris-HCl, pH 7.5; 120 mM NaCl; 20 mM NaF; 1 mM EDTA; 6 mM EGTA, 15 mM Na-pyrophosphate; 1 mM PMSF and 0.1% NP40. Extracts were clarified by centrifugation for 30 min at 14.000 r.p.m. and then incubated for 1 h with glutathione-sepharose beads which had been loaded with . After washing the beads three times in lysis buffer, they were incubated for 30 min at 371C in kinase buffer containing [g-32 P]ATP (see above). The reaction mixture was then analysed as described above. Alternatively, a nonradioactive kinase assay was performed. In this case, sepharose beads loaded with GST-Jun(1-135) were incubated with cell extract, washed as above and incubated for 30 min at 371C in kinase buffer lacking radioactive ATP. The reaction mixture was then analysed by SDS-PAGE and Western blotting with antibody specific for c-Jun phosphorylated at serine 63 (sc-822, St Cruz).
Bacterial expression of GST-fusion proteins and pull-down experiments
GST fusion protein expression was induced in logarithmically growing cultures of transformed bacteria (Escherichia coli BL21-lys) by adding iso-b-D-thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM. After additional 3 h of growth, the bacteria were harvested by centrifugation for 10 min at 8000 r.p.m., resuspended in GST-Lysis-buffer (50 mM TrisHCl, pH 8.0; 150 mM NaCl; 1% Triton X-100; 1 mM DTT; 0.1 mM PMSF) and lysed by three freeze-thaw cycles and sonification. An extract of soluble protein was prepared by ultracentrifuagtion for 1 h at 45 000 r.p.m. (SW 50.1 rotor). Extract containing 5-10 mg of GST fusion protein was then mixed with 50 ml of glutathione-Sepharose (Pharmacia) and incubated at 41C for 1 h. Afterwards, the sepharose beads were washed three times with phosphate-buffered saline (PBS) and used for GST pull-down assays of total cell extracts as follows. QT6 cells transfected with the appropriate expression vectors were lysed in buffer containing 50 mM Tris-HCl, pH 7.5; 120 mM NaCl; 20 mM NaF; 1 mM EDTA; 6 mM EGTA; 15 mM sodiumpyrophosphate; 1 mM PMSF and 0.1% NP40. Equal aliquots of the lysate were then incubated under constant agitation for 1 h at 41C with bacterially expressed GST fusion protein coupled to glutathione-sepharose. The sepharose beads were then washed with lysis buffer, the proteins were eluted from the beads with SDS sample buffer and analysed by SDS-polyacrylamide gel electrophoresis and Western blotting.
